Constantine Gennatas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Constantine Gennatas has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Vasiliki Michalaki
Oncology Clinic Second Department of Surgery, Athens Medical School, Athens, Greece Areteion Hospital, 76 V.Sofias av, 115 28, Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 23 April 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 115
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown to have significant clinical benefit in advanced renal cell carcinoma.
- 23 April 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 115
Open AccessChromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown to have significant clinical benefit in advanced renal cell carcinoma.